• Xpovio Leads to Promising Responses in Heavily Treated Multiple Myeloma Patients, Phase 2 Trial Shows
  • Myeloma Crowd Invites Patients to Join Study Investigating Link Between Psoriasis and Myeloma
  • New MMRF Patient Registry Aims to Help Develop Personalized Treatments for Multiple Myeloma
  • Pomalyst Combo Appears Effective in Multiple Myeloma Patients Refractory to Revlimid, Trial Reports
  • Chinese Regulatory Agency Clears CT103A for Clinical Studies in Relapsed or Refractory Multiple Myeloma
  • Aplidin Prolongs Survival and Time to Disease Progression in Heavily Treated Multiple Myeloma Patients, Phase 3 Trial Shows
  • Bone Marrow Macrophages Could Predict Resistance to Velcade, Study Suggests
  • Darzalex, Kyprolis, Dexamethasone Combo Extends Time to Disease Progression in Relapsed, Refractory Multiple Myeloma Patients, CANDOR Trial Results Show
  • FDA Approves Darzalex Combo for Newly Diagnosed Multiple Myeloma Patients Eligible for Transplant
  • CLR 131 Granted Orphan Drug Status in Europe for Myeloma Treatment
  • Carsgen’s CAR-T Cell Therapy Given Priority Designation in Europe for Multiple Myeloma
  • Darzalex Combo Increases Response Rates in Newly Diagnosed Multiple Myeloma Patients, Trial Shows